Search

everythinglearnresearchcommunity

for

Search:↓

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

Tofacitinib helped a man with alopecia totalis regrow all his hair.

JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

A new compound shows promise as a topical treatment for hair loss.

Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.

Baricitinib successfully treated myasthenia gravis and alopecia in a patient.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

Baricitinib shows promise for treating alopecia areata with mild side effects.

Natural compounds may help treat advanced papillary thyroid cancer by targeting specific molecular pathways.

Rapamycin reduces skin cell growth and tumor development by affecting cell signaling in mice.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

Janus kinase inhibitors are effective and safe for treating Alopecia Areata.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Panitumumab treatment can cause unusual hair growth in some colorectal cancer patients.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.